Gillian Mcgovern

Ashlan Kunz Coyne, PharmD, MPH, discusses treating Pseudomonas–Stenotrophomonas coinfections, co-culture insights, and smart empiric therapy amid rising resistance.

MS care shifts to smoldering progression and biomarkers; learn how pharmacists guide DMT choices, monitoring, and emerging BTK inhibitor therapy.

GLP-1 receptor agonists may reduce asthma flare-ups in nondiabetic adults with obesity, hinting at anti-inflammatory benefits.

This FAQ covers current dispensing regulations, practical considerations for pharmacists, and the clinical pharmacology of mifepristone.

Real-world data reveal that moderate to severe depression is linked to poor control and adherence, and women are more likely to be impacted.

Listen Key Takeaways Antibody–drug conjugates couple a tumor-targeting monoclonal antibody to a cytotoxic payload via a linker, aiming to maximize intratumoral delivery and reduce systemic exposure.

New findings suggest that differences in immune reconstitution kinetics may drive variations in graft-versus-host disease incidence, infection risk, and overall survival.

Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children, adolescent, and adult patients with diabetes.

Findings presented at the 2026 Joint ASTCT + EBMT Basic and Translational Scientific Meeting offer potential therapeutic targets to reduce GI toxicity and GVHD.

An RNA- and lipid nanoparticle-based platform derived from non-LTR transposons enables stable in vivo CAR T-cell engineering.